Intellia Therapeutics (NASDAQ:NTLA) Stock Upgrade

Intellia Therapeutics (NASDAQ:NTLA) Shares were upgraded by research professionals at BidaskScore to a solid Buy rating in analysts note published on 27 November.

The stock increased 1.91% or $0.33 during the last trading session, reaching $17.33. About 490,964 shares traded. Intellia Therapeutics, Inc. (NASDAQ:NTLA) has declined 29.82% since November 29, 2018 and is downtrending. It has underperformed by 29.82% the S&P500.

Analysts await Intellia Therapeutics, Inc. (NASDAQ:NTLA) to report earnings on February, 26. They expect $-0.53 earnings per share, down 23.26 % or $0.10 from last year’s $-0.43 per share. After $-0.49 actual earnings per share reported by Intellia Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 8.16 % negative EPS growth.

Intellia Therapeutics Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company has market cap of $847.13 million. The firm develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs. It currently has negative earnings. The Company’s ex vivo pipeline includes proprietary and partnered programs focuses on chimeric antigen receptor T cells and hematopoietic stem cells.

More notable recent Intellia Therapeutics, Inc. (NASDAQ:NTLA) news were published by: which released: “U.S. Housing Starts Jump 3.8% In October – Nasdaq” on November 19, 2019, also with their article: “BUZZ-U.S. STOCKS ON THE MOVE-Retail stocks, Slack, AT&T, Myovant Sciences – Nasdaq” published on November 19, 2019, published: “Gene editors rally on Vertex/Crispr deal – Seeking Alpha” on June 07, 2019. More interesting news about Intellia Therapeutics, Inc. (NASDAQ:NTLA) were released by: and their article: “Editas (NASDAQ:EDIT), Intellia (NASDAQ:NTLA) and CRISPR Therapeutics (NASDAQ:CRSP) Have Enormous Upside According to Manisha Samy – The Wall Street Transcript” published on April 11, 2019 as well as‘s news article titled: “51 Stocks Moving In Tuesday’s Mid-Day Session – Benzinga” with publication date: November 19, 2019.

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Source link